November 24, 2016 - By Peter Erickson · 0 Comments
The stock of Arqule Incorporated (NASDAQ:ARQL) registered an increase of 34.56% in short interest. ARQL’s total short interest was 205,200 shares in November as published by FINRA. Its up 34.56% from 152,500 shares, reported previously. With 97,000 shares average volume, it will take short sellers 2 days to cover their ARQL’s short positions. The short interest to Arqule Incorporated’s float is 0.44%. The stock closed at $1.38 during the last session. It is down 25.00% since April 22, 2016 and is downtrending. It has underperformed by 30.41% the S&P500.
ArQule, Inc. is a biopharmaceutical company. The company has a market cap of $98.14 million. The Firm is engaged in the research and development of therapeutics to treat cancers and rare diseases. It currently has negative earnings. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications.
Out of 2 analysts covering ArQule (NASDAQ:ARQL), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. ArQule has been the topic of 2 analyst reports since December 9, 2015 according to StockzIntelligence Inc. As per Wednesday, December 9, the company rating was reinitiated by Leerink Swann. The stock has “Outperform” rating given by RBC Capital Markets on Monday, December 21.
ArQule, Inc., incorporated on January 1, 1994, is a biopharmaceutical company. The Firm is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. The Company’s clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company’s lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company’s product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.
More news for ArQule, Inc. (NASDAQ:ARQL) were recently published by: Marketwatch.com, which released: “ArQule stock price target raised to $5 from $4 at RBC Capital” on October 31, 2010. Seekingalpha.com‘s article titled: “ArQule Is Undervalued Going Into Catalyst Events” and published on October 21, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Peter Erickson